Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as ...

A machine learning model using existing clinical data may help clinicians screen for comorbid anxiety and depression in ...

Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...

Combining genetic and symptom-based risk scores to predict MS may accelerate the diagnosis of the disease, according to a new ...

A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...

A post-hoc analysis of phase 3 trials presented at ACTRIMS Forum 2025 suggests that tolebrutinib may be more effective in MS ...

A six-month modified Atkins diet intervention in relapsing multiple sclerosis patients led to significant immunometabolic ...

Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who had a greater number of MRI paramagnetic rim lesions at baseline, data show ...

Q4 2024 Earnings Call Transcript March 3, 2025 TG Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.15, ...

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis – Vidofludimus Calcium’s Activation of Nurr1 Reduces ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase II results of orelabrutinib ...

As a premier global event in neuroimmunology, ACTRIMS gathered scholars and experts specializing in neuroimmunology from around the world to jointly explore the cutting-edge developments in ...